advised that information on this matter may be obtained by contacting the National Endowment for the Humanities' TDD terminal at (202) 606– 8282

Dated: November 22, 2017.

#### Elizabeth Voyatzis,

Committee Management Officer. [FR Doc. 2017–25712 Filed 11–27–17; 8:45 am]

BILLING CODE 7536-01-P

## NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES

### Humanities Panel Advisory Committee; Charter Renewal

**AGENCY:** National Endowment for the Humanities.

**ACTION:** Notice of Charter Renewal for Humanities Panel advisory committee.

**SUMMARY:** Pursuant to section 9(a)(2) of the Federal Advisory Committee Act and its implementing regulations, the National Endowment for the Humanities (NEH) gives notice that the Charter for the Humanities Panel advisory committee will be renewed for an additional two-year period on November 24, 2017. The Chairman of NEH determined that the renewal of the Humanities Panel is necessary and in the public interest in connection with the performance of duties imposed upon the Chairperson of NEH by the National Foundation on the Arts and the Humanities Act of 1965, as amended.

## FOR FURTHER INFORMATION CONTACT:

Elizabeth Voyatzis, Committee
Management Officer, 400 Seventh Street
SW., Washington, DC 20506. Telephone:
(202) 606–8322, facsimile (202) 606–
8600, or email at gencounsel@neh.gov.
Hearing-impaired individuals are
advised that information on this matter
may be obtained by contacting the
National Endowment for the
Humanities' TDD terminal at (202) 606–
8282.

Dated: November 22, 2017.

#### Elizabeth Voyatzis,

Committee Management Officer. [FR Doc. 2017–25711 Filed 11–27–17; 8:45 am]

BILLING CODE 7536-01-P

# NUCLEAR REGULATORY COMMISSION

[Docket No. 50-609; NRC-2013-0235]

Northwest Medical Isotopes, LLC; Notice of Hearing

**AGENCY:** Nuclear Regulatory Commission.

**ACTION:** Construction permit application; notice of hearing.

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC or the Commission) will convene an evidentiary session to receive testimony and exhibits in the uncontested proceeding regarding the application from Northwest Medical Isotopes, LLC (NWMI), for a construction permit (CP) to construct a medical radioisotope production facility in Columbia, Missouri. This mandatory hearing will consider safety and environmental matters relating to the requested CP.

DATES: The hearing will be held on January 23, 2018, beginning at 9:00 a.m. Eastern Time. For the schedule for submitting pre-filed documents and deadlines affecting Interested Government Participants, see Section VI of the SUPPLEMENTARY INFORMATION section of this document.

ADDRESSES: Please refer to Docket ID 50–609 when contacting the NRC about the availability of information regarding this document. You may obtain publicly available information related to this document using any of the following methods:

- NRC's Electronic Hearing Docket: You may obtain publicly available documents related to this hearing on line at http://www.nrc.gov/about-nrc/ regulatory/adjudicatory.html.
- NRC's Agencywide Documents Access and Management System (ADAMS): You may obtain publicly available documents online in the ADAMS Public Documents collection at http://www.nrc.gov/reading-rm/ adams.html. To begin the search, select "ADAMS Public Documents," and then select "Begin Web-based ADAMS Search." For problems with ADAMS, please contact the NRC's Public Document Room (PDR) reference staff at 1–800–397–4209, 301–415–4737, or by email to pdr.resource@nrc.gov. The ADAMS accession number for each document referenced (if that document is available in ADAMS) is provided the first time that a document is referenced.
- NRC's PDR: You may examine and purchase copies of public documents at the NRC's PDR, Room O1–F21, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852.

#### FOR FURTHER INFORMATION CONTACT:

Denise McGovern, Office of the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC 20555– 0001, telephone: 301–415–0681; email: Denise.McGovern@nrc.gov.

### SUPPLEMENTARY INFORMATION:

#### I. Background

The Commission hereby gives notice that, pursuant to Section 189a of the Atomic Energy Act (AEA) of 1954, as amended (the Act), it will convene an evidentiary session to receive testimony and exhibits in the proceeding regarding the NWMI application for a CP under part 50 of title 10 of the *Code of Federal Regulations* (10 CFR), to construct a medical radioisotope production facility in Columbia, Missouri.

Part one of NWMI's two-part application was submitted by letter dated February 5, 2015 (ADAMS Accession No. ML15086A261), and by letter dated July 20, 2015 (ADAMS Accession No. ML15210A182), NWMI submitted the second part of its application. Revision 3 of the application may be viewed at ADAMS Accession No. ML17257A019.

The NRC staff's Environmental Impact Statement and Safety Evaluation Report may be viewed at ADAMS Accession Nos. ML17130A862 and ML17310A365, respectively. This mandatory hearing will concern safety and environmental matters relating to the requested construction permit application, as more fully described below.

## II. Evidentiary Uncontested Hearing

The Commission will conduct this hearing beginning at 9:00 a.m., Eastern Time on January 23, 2018, at the Commission's headquarters in Rockville, Maryland. The hearing will continue on subsequent days, if necessary.

### III. Presiding Officer

The Commission is the presiding officer for this proceeding.

#### IV. Matters To Be Considered

The matter at issue in this proceeding is whether the review of the NWMI CP application by the Commission's staff has been adequate to support the findings found in 10 CFR 50.35, 50.40, 50.50, and 10 CFR 51.105. Those findings are as follows:

Issues Pursuant to the Atomic Energy Act of 1954, as Amended

With respect to the CP: (1) Whether the applicant has described the proposed design of the facility, including, but not limited to, the principal architectural and engineering criteria for the design, and has identified the major features or components incorporated therein for the protection of the health and safety of the public; (2) whether such further technical or design information as may be required to complete the safety analysis, and which can reasonably be